WO2005000313A1 - 抗てんかん剤 - Google Patents
抗てんかん剤 Download PDFInfo
- Publication number
- WO2005000313A1 WO2005000313A1 PCT/JP2004/009358 JP2004009358W WO2005000313A1 WO 2005000313 A1 WO2005000313 A1 WO 2005000313A1 JP 2004009358 W JP2004009358 W JP 2004009358W WO 2005000313 A1 WO2005000313 A1 WO 2005000313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- same
- formula
- different
- lower alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Definitions
- the present invention relates to an antiepileptic agent containing a xanthine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
- Epilepsy as defined by the World Health Organization (WHO), is a chronic brain disorder caused by a variety of etiologies, with a major recurrent seizure (epileptic seizure) resulting from excessive firing of cerebral neurons. It is characterized by various clinical symptoms and laboratory findings. " Epileptic seizures take various forms, such as impaired consciousness, convulsions, and automatism, depending on where the sudden onset of spontaneous cerebral rhythm abnormalities and how they spread. In epilepsy, in addition to epileptic seizures, for example, periodic dysfunction, intermittent mental disorder, personality change, intellectual disorder, etc. are often observed.
- anti-epileptic drugs such as norbital, such as phenobarbital, benzodiazepines, such as clonazepam, and valproic acid.
- Antiepileptic drugs are currently used, and it is said that seizures are completely suppressed by drug administration in about 80% of epilepsy patients.
- xanthine derivatives containing the compound represented by the formula (I) described below have, for example, an antiparkinson's disease action, a central stimulating action, an inhibitory action on neurodegeneration, and the like (Japanese Patent Publication No. 47-26516). JP-A-6-211856; JP-A-6-239862; JP-A-6-16559; WO 99/12546, etc.). It is also known to have, for example, adenosine A 2. Receptor antagonism, antidepressant action, anti-asthma action, bone resorption inhibitory action, hypoglycemic action, platelet proliferation inhibitory action (International Publication No. 92/92).
- An object of the present invention is to provide an excellent antiepileptic agent.
- the present invention relates to the following (1) to (7).
- Ri, R 2 and R 3 are the same or different and represent a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl,
- Y 1 and Y 2 are the same or different and represent a hydrogen atom, a halogen or a lower alkyl, and Z represents a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group).
- ⁇ and X 2 are the same or different and represent an oxygen atom or a sulfur atom.] Or a pharmacologically acceptable salt thereof as an active ingredient.
- R4 is the formula ( ⁇ )
- R 6 is a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, (3) or (4), which represents nitrogen or amino, and m represents an integer of 1'3).
- a method for treating epilepsy characterized by:
- compound (I) the compound represented by the formula (I) is referred to as compound (I).
- lower alkyl moiety of lower alkyl and lower alkoxy examples include straight-chain or branched alkyl having 1 to 6 carbon atoms. Specific examples include methyl, ethyl, propyl, isopropyl, butynole, isoptinole, and sec. -Butyl, tert-butyl, pentyl, neopentinole, hexinole, and the like.
- Examples of the lower alkenyl include straight-chain or branched alkenyl having 2 to 6 carbon atoms.
- Examples of the lower alkynyl include straight-chain or branched alkynyl having 2 to 6 carbon atoms, and specific examples thereof include ethur, propargyl, 2-butynyl, 3-butyninole, 2-pentyninole, and 4-pentyne. Ninore, 2-hexinole, 5-hexinole, 4-methinole-2-pentul and the like.
- cycloalkyl examples include cycloalkyl having 3 to 8 carbon atoms, and specific examples thereof include propyl, cyclobutyl, cyclopentyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. .
- Halogen refers to fluorine, chlorine, bromine, and iodine atoms.
- aryl include aryl having 6 to 14 carbon atoms, and specific examples include phenyl, naphthyl and anthryl.
- the heterocyclic group includes, for example, a 5- or 6-membered monocyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and a bicyclic ring obtained by condensing a 3- to 8-membered ring or tricyclic nitrogen atom, condensed heterocyclic group containing an oxygen atom and t least one atom Ru are selected from sulfur atom and the like, in particular flip-le, thienyl, pyrosulfate Lil, Biraniru , Thiopyranyl, pyridyl, pyrimidinyl, 'triazinyl, purinyl, pyrazinyl, pyridazinyl, benzimidazolyl, 2-oxobenzoimidazolinole, benzotriazolinole, benzofurinole, benzothienole, benzoxazolinole, benzothiazolinole
- the substituents in the substituted aryl and the substituted heterocyclic groups may be the same or different, for example, having 1 to 3 substituents, specifically, lower alkyl, lower alkenyl, lower alkynyl, hydroxy, substituted or unsubstituted lower alkoxy.
- Halogen Nitro, Amino, Lower Alkylamino, Lower Alkylamino, Trifluoromethinole, Trifnorolelomethoxy, Aralanolequinole, Aranolequinoleoxy, Arinole, Ryroloxy, Lower Alkanol, Lower Alkanol , Arroynole, Ryroyloxy, Arylalkanoyloxy, Carboxy, Lower Alkoxyl Luponyl, Lower Alkyl Rubamoyl, Di-Lower Alkyl Canolebamoyl, Snorejo, Lower Anolecoxysulfonyl, Lower Anolecilsulfamoyl, And lower alkyl sulfamoyl.
- the above-mentioned lower alkyl, and halogen, lower alkenyl and lower alkynyl have the same meanings as above.
- the two lower alkyl moieties of difamoyl may be the same or different.
- the aryl and aryloxy have the same meaning as the aryl and include, for example, benzyl and phenethyl.
- Examples of the alloy part of aroyl and arylooxy include benzoyl and naphthoyl.
- the arylalkyl moiety of arylalkanoloxy includes, for example, Benzinole, Fene Chill and the like.
- Examples of the substituent in the substituted lower alkoxy include hydroxy, lower alkoxy, halogen, amino, azido, carboxy, lower alkoxycarbonyl and the like.
- the lower alkyl part of the lower alkoxy and the lower alkoxycarbonyl has the same meaning as the lower alkyl, and the nitrogen is the same as the above.
- Examples of the pharmacologically acceptable salt of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- Pharmaceutically acceptable acid addition salts of compound (I) include, for example, inorganic acid salts such as hydrochloride, sulfate, phosphate, etc., acetate, maleate, fumarate, tartrate, and taenoic acid Salts and organic acid salts such as methanesulfonate.
- Pharmacologically acceptable metal salts include, for example, sodium metal salts, aluminum salt metal salts such as potassium salt, and magnesium salt.
- pharmacologically acceptable ammonium salts include, for example, salts such as ammonium, tetramethylammonium, etc.
- Organically acceptable addition salts of organic amines include addition salts such as morpholine and piperidine, and pharmacologically acceptable addition salts of amino acids include addition salts such as lysine, glycine, and phenylalanine. Ah It is.
- the target compound in each production method can be isolated and purified by a purification method commonly used in synthetic organic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, various types of chromatography, and the like.
- compound (I) when it is desired to obtain a salt of compound (I), if compound (I) is obtained in the form of a salt, it can be purified as it is, and if it can be obtained in the form of a free base, use an appropriate solvent. It may be dissolved or suspended, and an acid or a base may be added to form a salt.
- Compound (I) and its pharmacologically acceptable salts may exist in the form of adducts with water or various solvents, and these adducts can also be used in the antiepileptic agent of the present invention. .
- Some of the compounds (I) may have optical isomers and the like, and all possible stereoisomers and mixtures thereof can be used in the antiepileptic agent of the present invention.
- Table 1 shows specific examples of the compound (I).
- OAV Compound (I) was orally administered at 30 mg / kg (volume of 10 mL / kg) (test compound administration group). Separately, a 0.5% MC solution alone was orally administered at 10 ml / kg to reserpine-treated mice as a solvent administration group. One hour later, a shock stimulant (model: USA-201, Unique Medical Co., Ltd.) was used to give an electric shock of 1000 V, 50 mA, 0.2 seconds to the mice to induce tonic extension convulsions. The duration in the administration group was compared with that of the untreated group and the vehicle administration group. Fig. 1 shows the results.
- the duration of convulsions was significantly prolonged in the reserpine-treated vehicle-administered group compared to the untreated group (p ⁇ 0.001: Student's-test).
- the test compound-administered group to which compound 1 or 3 was administered a significant shortening effect on the duration of convulsions was observed as compared with the reserpine-treated vehicle-administered group (p ⁇ 0.01: Aspine-Welch test).
- Compound (I) or a pharmacologically acceptable salt thereof has an antiepileptic effect, which suggests that it is effective for prevention and / or treatment of epilepsy and epilepsy-based diseases. .
- Test example 2 Acute toxicity test
- the test compound was orally administered to three dd male mice (body weight: 20 ⁇ lg), three per group.
- the death status on the 7th day after administration was observed, and the minimum lethal dose (MLD) value was determined.
- MLD minimum lethal dose
- Epilepsy that is prevented and / or treated by administration of the antiepileptic agent of the present invention includes, for example, essential epilepsy of unknown origin, collectively referred to as epileptic seizures, and symptomatic epilepsy caused by intracerebral lesions (eg, Jackson epilepsy, West syndrome, Lennox-Gastaut syndrome, etc.), and febrile seizures.
- Epileptic seizures include, for example, (1) partial (focal, focal) seizures (i) simple partial seizures, (ii) complex partial seizures, and (iii) generalized seizures secondary to partial seizures (2) Classified as spastic and non-convulsive generalized seizures (i) absence seizures, (ii) myoclonic seizures, (iii) clonic seizures, (iv) tonic seizures, (V) tonic seizures Clonic seizures, (vi) weakness seizures, and (3) status epilepticus.
- the antiepileptic agent of the present invention is particularly preferably used especially for seizures with convulsions, specifically, simple partial seizures with convulsions, tonic seizures, clonic seizures, tonic-clonic seizures or myoclonic seizures. Seizures occur in a complex manner, such as a major seizure,
- Compound (I) or a pharmaceutically acceptable salt thereof can be used as it is or in various pharmaceutical forms.
- the pharmaceutical composition of the present invention can be produced by uniformly mixing an effective amount of compound (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier as an active ingredient.
- These pharmaceutical compositions are desirably in a unit dosage form suitable for administration, for example, rectally, orally or parenterally (including subcutaneously, intravenously and intramuscularly). '
- any useful pharmaceutically acceptable carrier can be used.
- oral liquid preparations such as suspensions and syrups include water, sucrose, sorbitol, saccharides such as fructose, polyethylene glycol cornole, glycolones such as propylene glycol and cornole, sesame oil, and olive oil.
- oils such as soybean oil
- P - preservatives such as arsenate Dorokishi benzoic acid esters
- be sampled port berry flavors, c powders which can be prepared using flavors such as peppermint, pills, capsules and tablets , Ratchet, glucose, sucrose, mannitol, etc., shaping agents such as starch, sodium alginate, lubricants such as magnesium stearate, talc, polyvinyl alcohol, hydroxypropyl cellulose, gelatin Binders, surfactants such as fatty acid esters, plasticizers such as glycerin, etc. It can be prepared using. Tablets and capsules are the most useful unit oral dosage forms because of their ease of administration. When producing tablets and capsules, solid pharmaceutical carriers are used.
- an injection can be prepared using a carrier composed of distilled water, a salt solution, a glucose solution or a mixture of salt water and a glucose solution. At this time, it is prepared as a solution, suspension or dispersion using a suitable auxiliary according to a conventional method.
- Compound (I) or a pharmacologically acceptable salt thereof can be administered orally in the above-mentioned pharmaceutical form or parenterally as an injection or the like. Although it depends on the form, age, weight, symptoms, etc. of the patient, it is appropriate to administer 1 to: L00mgZ60kg / day, preferably l to 20mgZ60kgZ, once or several times.
- FIG. 1 shows the effects of Compounds 1 and 3 on the prolonged duration of tonic convulsions caused by reserpine administration and electric shock stimulation.
- the vertical axis represents the duration (seconds) of tonic extension convulsions, and the bar graphs show, in order from the left, the untreated group, the vehicle-administered group, the compound 1-administered group, and the compound 3-administered group.
- the meanings of the symbols on the graph are as follows.
- Example 1 Tablets ''
- a tablet having the following composition is prepared by a conventional method.
- a capsule having the following composition is prepared by a conventional method.
- An injection having the following composition is prepared by a conventional method.
- Purified soybean oil 200 mg Purified egg yolk lecithin 24 mg Injectable glycerin 50 mg
- a formulation for rectal administration having the following composition is prepared by a conventional method.
- an antiepileptic agent containing an X. santin derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002530649A CA2530649A1 (en) | 2003-06-27 | 2004-06-25 | Antiepileptic agent |
EP04746827A EP1640007A1 (en) | 2003-06-27 | 2004-06-25 | Antiepileptic agent |
JP2005511112A JPWO2005000313A1 (ja) | 2003-06-27 | 2004-06-25 | 抗てんかん剤 |
US10/560,598 US20060122198A1 (en) | 2003-06-27 | 2004-06-25 | Antiepileptic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-185477 | 2003-06-27 | ||
JP2003185477 | 2003-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005000313A1 true WO2005000313A1 (ja) | 2005-01-06 |
Family
ID=33549666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009358 WO2005000313A1 (ja) | 2003-06-27 | 2004-06-25 | 抗てんかん剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060122198A1 (ja) |
EP (1) | EP1640007A1 (ja) |
JP (1) | JPWO2005000313A1 (ja) |
CA (1) | CA2530649A1 (ja) |
WO (1) | WO2005000313A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065595A2 (en) * | 2005-12-07 | 2007-06-14 | Ucb Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107249583B (zh) | 2015-02-09 | 2021-05-07 | 国立大学法人冈山大学 | 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006976A1 (fr) * | 1990-10-18 | 1992-04-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de xanthine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756735A (en) * | 1990-10-18 | 1998-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
-
2004
- 2004-06-25 US US10/560,598 patent/US20060122198A1/en not_active Abandoned
- 2004-06-25 EP EP04746827A patent/EP1640007A1/en not_active Withdrawn
- 2004-06-25 WO PCT/JP2004/009358 patent/WO2005000313A1/ja not_active Application Discontinuation
- 2004-06-25 CA CA002530649A patent/CA2530649A1/en not_active Abandoned
- 2004-06-25 JP JP2005511112A patent/JPWO2005000313A1/ja not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006976A1 (fr) * | 1990-10-18 | 1992-04-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de xanthine |
Non-Patent Citations (2)
Title |
---|
DE SARRO G. ET AL.: "Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 371, no. 2/3, 1999, pages 137 - 145, XP001004557 * |
KLITGAARD H. ET AL.: "Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 242, no. 3, 1993, pages 221 - 228, XP002981451 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065595A2 (en) * | 2005-12-07 | 2007-06-14 | Ucb Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
WO2007065595A3 (en) * | 2005-12-07 | 2007-08-23 | Ucb Pharma Sa | Xanthine derivatives, processes for preparing them and their uses |
Also Published As
Publication number | Publication date |
---|---|
US20060122198A1 (en) | 2006-06-08 |
JPWO2005000313A1 (ja) | 2006-08-03 |
CA2530649A1 (en) | 2005-01-06 |
EP1640007A1 (en) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009102334A (ja) | 神経変性疾患治療剤 | |
JP2015007096A (ja) | 運動障害の予防および/または治療剤 | |
EP1738766A1 (en) | Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain | |
EP0503471A1 (de) | Neue acylaminosubstituierte Hetrazepine | |
JPH0755949B2 (ja) | 新規ピリド〔2,3−d〕ピリミジン誘導体、その製造方法並びに該化合物を含有する医薬組成物 | |
WO2005000313A1 (ja) | 抗てんかん剤 | |
CN114344313A (zh) | 用于预防或治疗神经系统退行性疾病的白桦脂酸衍生物 | |
CN114392262A (zh) | 抑制神经系统退行性疾病的白桦脂酸衍生物 | |
CA2554426C (en) | Agents for treating migraine | |
RU2093155C1 (ru) | Применение 5-[2-хлор-1-гидроксиэтил]-4-метилтиазола для снижения поражения нейронов, подавления конвульсий и снижения двигательной активности | |
JP2009143929A (ja) | 睡眠障害の予防・治療剤 | |
CA2388176C (en) | Therapeutic agent for eating disorders | |
EP2514753B1 (en) | 6,7-Dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation | |
JPH0138089B2 (ja) | ||
JPWO2006059713A1 (ja) | 薬物依存症の予防および/または治療剤 | |
WO1998057644A1 (fr) | Agent de prevention et remede contre la nephropathie induite par les medicaments | |
CA2550130A1 (en) | Agents for preventing and/or treating higher brain dysfunctions | |
CA2299909C (en) | Therapeutic agent for neurodegenerative disorders | |
JPH04270222A (ja) | 脳機能改善剤 | |
MXPA06005965A (en) | Preventive and/or therapeutic agent for higher brain dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511112 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006122198 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10560598 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004746827 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2530649 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004746827 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10560598 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004746827 Country of ref document: EP |